VSCP VirtualScopics, Inc. featured news, full reports, and detailed charts
VirtualScopics, Inc. (VSCP) Wrap Up:
VirtualScopics, Inc., is a provider of image-based biomarker solutions to customers in the pharmaceutical, biotechnology and medical device industries that are designed to facilitate cost-effective drug and medical device development. We are headquartered in Rochester, New York. Corporate History We are a Delaware corporation originally formed in 1988 under the name ConsultAmerica, Inc. On November 4, 2005, we acquired all of the outstanding membership units of VirtualScopics, LLC, in exchange for 17,326,571 shares of our common stock, and changed our name to VirtualScopics, Inc. At the time of the transaction, the newly issued shares constituted approximately 70% of the outstanding shares of common stock and shares of common stock initially issuable upon the conversion of our outstanding series A convertible preferred stock. ConsultAmerica, Inc. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f18%2f0001144204-08-016147.html#FIS_BUSINESS"VirtualScopics Inc. (VSCP:NASDAQ)
Snapshot of VirtualScopics Inc. (VSCP)
|
OPEN
$1.17
|
PREVIOUS CLOSE
$1.17
|
|
|
DAY HIGH
$1.17
|
DAY LOW
$1.16
|
|
|
52 WEEK HIGH
08/3/09 - $1.68
|
52 WEEK LOW
12/15/08 - $0.38
|
|
|
MARKET CAP
29.1M
|
AVERAGE VOLUME 3 mo
40.2K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
24.9M
|
|
|
VSCP Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
VSCP Top Compensated Officers
Executives, Board Directors
Key developments for VirtualScopics Inc. (VSCP)
VirtualScopics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenues of $2,797,680, operating income of $189,326, net loss attributable to common stockholders of $291,383 or basic and diluted net loss per common share of $0.01 against revenues of $1,815,616, operating loss of $553,968, net loss attributable to common stockholders of $633,132 or basic and diluted net loss per common share of $0.03 for the same period last year. Earnings before interest, taxes, depreciation and amortization, and excluding stock compensation expense and a loss from derivative financial instrument ('Adjusted EBITDA') was $581,862 for the quarter ended September 30, 2009 compared to Adjusted LBITDA of $201,134 for the comparable period in 2008. For the nine months, the company reported revenues of $7,473,366, operating loss of $371,790, net loss attributable to common stockholders of $1,629,659 or basic and diluted net loss per common share of $0.07 against revenues of $5,183,017, operating loss of $2,372,350, net loss attributable to common stockholders of $2,578,515 or basic and diluted net loss per common share of $0.11 for the same period last year. Net cash flows provided by operating activities was $1,019,024 against net cash used in operating activities of $950,434 for the same period last year. For the nine months ended September 30, 2009, Adjusted LBITDA was $803,655 compared to $1,097,894 for the first nine months of 2008. The company provided guidance at the beginning of this year to generate between $9 million and $10 million in revenues. The company well on its way to achieve its high estimate of $10 million.
VirtualScopics Inc., Q3 2009 Earnings Call, Nov-12-2009
To present a corporate and financial overview
VSCP Competitors
| Company | Last | Change |
| BioClinica Inc | $4.11 USD | -0.069 |
| Vital Images Inc | $12.60 USD | -0.05 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | VSCP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.0x |
|
| Price/Book | 6.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.7x |
|
|
VSCP |
||
VSCP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
